RU2004123794A - HIGH-SENSITIVE AND CONTINUOUS PROTEINTHYROSINPHOSPHATASE TEST USING 6,8-DIFTOR-4-METHYLUMBELLIPHERyl PHOSTATE - Google Patents

HIGH-SENSITIVE AND CONTINUOUS PROTEINTHYROSINPHOSPHATASE TEST USING 6,8-DIFTOR-4-METHYLUMBELLIPHERyl PHOSTATE Download PDF

Info

Publication number
RU2004123794A
RU2004123794A RU2004123794/15A RU2004123794A RU2004123794A RU 2004123794 A RU2004123794 A RU 2004123794A RU 2004123794/15 A RU2004123794/15 A RU 2004123794/15A RU 2004123794 A RU2004123794 A RU 2004123794A RU 2004123794 A RU2004123794 A RU 2004123794A
Authority
RU
Russia
Prior art keywords
compound
biological material
difmup
ptp
difluoro
Prior art date
Application number
RU2004123794/15A
Other languages
Russian (ru)
Inventor
Штефан ВЕЛЬТЕ (DE)
Штефан ВЕЛЬТЕ
Норберт ТЕННАГЕЛЬС (DE)
Норберт Теннагельс
Штефан ПЕТРИ (DE)
Штефан Петри
Original Assignee
АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE)
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002100173 external-priority patent/DE10200173A1/en
Priority claimed from DE2002136329 external-priority patent/DE10236329A1/en
Application filed by АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE), Авентис Фарма Дойчланд Гмбх filed Critical АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE)
Publication of RU2004123794A publication Critical patent/RU2004123794A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. Способ обнаружения ферментативной активности протеинтирозинфосфатазы в биологическом материале, в котором1. A method for detecting the enzymatic activity of protein tyrosine phosphatase in biological material, in which а) готовят биологический материал или препарат из биологического материала;a) prepare biological material or a preparation from biological material; b) готовят 6,8-дифтор-4-метилумбеллиферилфосфат (DiFMUP);b) 6.8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) is prepared; с) биологический материал или препарат из биологического материала из а) вводят в контакт с DiFMUP из b) в водном растворе;c) biological material or a preparation of biological material from a) is contacted with DiFMUP from b) in an aqueous solution; d) образующийся 6,8-дифтор-4-метилумбеллиферил обнаруживают флуориметрически.d) the resulting 6,8-difluoro-4-methylumbelliferyl is detected fluorimetrically. 2. Способ по п.1, отличающийся тем, что в качестве препарата из биологического материала готовят по меньшей мере одну протеинтирозинфосфатазу, выбираемую из группы, состоящей из LAR, CD 45, YOP, PTP-альфа, РТР 1В, ТС-РТР, CDC 25, PTEN, SHP 1,2.2. The method according to claim 1, characterized in that at least one protein tyrosine phosphatase selected from the group consisting of LAR, CD 45, YOP, PTP-alpha, PTP 1B, TC-PTP, CDC is prepared from a biological material 25, PTEN, SHP 1.2. 3. Способ по п.1 или 2, отличающийся тем, что концентрация DiFMUP после введения в контакт составляет 10-250 мкмоль.3. The method according to claim 1 or 2, characterized in that the concentration of DiFMUP after contact is 10-250 μmol. 4. Способ по п.3, отличающийся тем, что концентрация DiFMUP составляет 50-100 мкмоль.4. The method according to claim 3, characterized in that the concentration of DiFMUP is 50-100 μmol. 5. Способ по п.1, отличающийся тем, что значение рН водного раствора в с) составляет от 5,0 до 8,0.5. The method according to claim 1, characterized in that the pH value of the aqueous solution in c) is from 5.0 to 8.0. 6. Способ по п.5, отличающийся тем, что значение рН составляет от 6,0 до 7,5.6. The method according to claim 5, characterized in that the pH value is from 6.0 to 7.5. 7. Способ по п. 5 или 6, отличающийся тем, что значение рН составляет 7,0.7. The method according to p. 5 or 6, characterized in that the pH value is 7.0. 8. Способ идентификации соединения, модифицирующего активность протеинтирозинфосфатазы, в котором8. A method for identifying a compound modifying the activity of protein tyrosine phosphatase, in which а) готовят химическое соединение;a) preparing a chemical compound; b) готовят биологический материал или препарат из биологического материала;b) preparing a biological material or preparation from a biological material; с) готовят 6,8-дифтор-4-метилумбеллиферилфосфат (DiFMUP);c) 6.8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) is prepared; d) химическое соединение из а), а также биологический материал или препарат из биологического материала из b) и DiFMUP из с) вводят в контакт друг с другом в водном растворе;d) the chemical compound from a) as well as the biological material or preparation from the biological material from b) and DiFMUP from c) are brought into contact with each other in an aqueous solution; е) флуориметрически определяют количество образующегося 6,8-дифтор-4-метилумбеллиферила;e) fluorimetrically determine the amount of 6,8-difluoro-4-methylumbelliferyl formed; f) количество образующегося 6,8-дифтор-4-метилумбеллиферила из е) сравнивают с количеством образующегося 6,8-дифтор-4-метилумбеллиферила в контрольной смеси.f) the amount of 6.8-difluoro-4-methylumbelliferyl formed from e) is compared with the amount of 6.8-difluoro-4-methylumbelliferyl formed in the control mixture. 9. Способ по п.8, отличающийся тем, что активность протеинтирозинфосфатазы стимулируют, ингибируют или сохраняют.9. The method according to claim 8, characterized in that the activity of protein tyrosine phosphatase stimulate, inhibit or maintain. 10. Способ по п.8 или 9, отличающийся тем, что протеинтирозинфосфатазу выбирают из группы, состоящей из LAR, CD 45, YOP, PTP-альфа, РТР 1В, ТС-РТР, CDC 25, PTEN, SHP 1,2.10. The method according to claim 8 or 9, characterized in that the protein tyrosine phosphatase is selected from the group consisting of LAR, CD 45, YOP, PTP-alpha, PTP 1B, TC-PTP, CDC 25, PTEN, SHP 1,2. 11. Соединение, идентифицируемое способом по п.п.8-10.11. The compound identified by the method according to claims 8-10. 12. Соединение по п.11, причем масса соединения составляет от 0,1 до 50 кДа.12. The compound according to claim 11, wherein the mass of the compound is from 0.1 to 50 kDa. 13. Соединение по п.11 или 12, причем масса соединения составляет от 0,1 до 5 кДа.13. The compound according to claim 11 or 12, and the mass of the compound is from 0.1 to 5 kDa. 14. Соединение по п. 13, причем масса соединения составляет от 0,1 до 3 кДа.14. The compound according to claim 13, wherein the mass of the compound is from 0.1 to 3 kDa. 15. Соединение по п.11, причем соединением является протеин, аминокислота, полисахарид, сахар, полинуклеотид, нуклеотид, природное соединение или ароматический углеводород.15. The compound according to claim 11, wherein the compound is a protein, amino acid, polysaccharide, sugar, polynucleotide, nucleotide, natural compound or aromatic hydrocarbon. 16. Лекарственное средство, содержащее по меньшей мере одно соединение по п.п.11-15, вспомогательные для получения готовой формы лекарственного средства вещества и/или полимерные добавки.16. A medicinal product containing at least one compound according to claims 11-15, auxiliary substances and / or polymer additives for preparing the finished drug form. 17. Применение соединения по одному или нескольким пп.11-14 для получения лекарственного средства для лечения диабета.17. The use of a compound according to one or more of claims 11-14 for the manufacture of a medicament for the treatment of diabetes.
RU2004123794/15A 2002-01-04 2002-12-24 HIGH-SENSITIVE AND CONTINUOUS PROTEINTHYROSINPHOSPHATASE TEST USING 6,8-DIFTOR-4-METHYLUMBELLIPHERyl PHOSTATE RU2004123794A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2002100173 DE10200173A1 (en) 2002-01-04 2002-01-04 Detecting activity of protein-tyrosine phosphatase by detecting hydrolysis of 6,8-difluoro-4-methylumbelliferyl phosphate, useful for identifying modulators of the enzyme that can be used to treat diabetes
DE10200173.1 2002-01-04
DE10236329.3 2002-08-08
DE2002136329 DE10236329A1 (en) 2002-08-08 2002-08-08 Detecting activity of protein-tyrosine phosphatase by detecting hydrolysis of 6,8-difluoro-4-methylumbelliferyl phosphate, useful for identifying modulators of the enzyme that can be used to treat diabetes

Publications (1)

Publication Number Publication Date
RU2004123794A true RU2004123794A (en) 2005-04-20

Family

ID=26010898

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004123794/15A RU2004123794A (en) 2002-01-04 2002-12-24 HIGH-SENSITIVE AND CONTINUOUS PROTEINTHYROSINPHOSPHATASE TEST USING 6,8-DIFTOR-4-METHYLUMBELLIPHERyl PHOSTATE

Country Status (12)

Country Link
EP (1) EP1466009A2 (en)
JP (1) JP2005512600A (en)
KR (1) KR20040073539A (en)
CN (1) CN1612939A (en)
AU (1) AU2002361217A1 (en)
BR (1) BR0215452A (en)
CA (1) CA2471601A1 (en)
IL (1) IL162832A0 (en)
MX (1) MXPA04006361A (en)
NO (1) NO20043244L (en)
RU (1) RU2004123794A (en)
WO (1) WO2003056029A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100350045C (en) * 2003-08-21 2007-11-21 北京农业生物技术研究中心 Corn tyrosin protein phosphatase gene and its coding protein and use
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (en) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Enhancement of vanadium-containing phosphatase inhibitors by polyols
CN113155787A (en) * 2020-12-29 2021-07-23 武汉合研生物医药科技有限公司 Activity detection method of mutant enzyme SHP 2E 76K

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516305A (en) * 1998-05-12 2002-06-04 アメリカン・ホーム・プロダクツ・コーポレイション 2,3,5-Substituted biphenyls useful for treating insulin resistance and hyperglycemia

Also Published As

Publication number Publication date
NO20043244L (en) 2004-08-02
MXPA04006361A (en) 2004-10-04
IL162832A0 (en) 2005-11-20
CN1612939A (en) 2005-05-04
BR0215452A (en) 2004-11-23
CA2471601A1 (en) 2003-07-10
WO2003056029A3 (en) 2004-04-01
KR20040073539A (en) 2004-08-19
JP2005512600A (en) 2005-05-12
AU2002361217A1 (en) 2003-07-15
WO2003056029A2 (en) 2003-07-10
EP1466009A2 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
CN106290923B (en) One kind activation coagulation assay reagent and its application
EP1985697A1 (en) Modified phosphatases
TWI519241B (en) Collagen production promoting composition
SK9292003A3 (en) Novel mixtures of microbial enzymes
RU2381238C2 (en) Method of preparing glucose-sensitive polymer hydrogels
PT98564B (en) PROCESS FOR THE CONDUCT OF ENZYME CATALYZED PROCESSES WITH CRYSTALS RETICULATED AS A FORM OF FIXING ENZYMES AND DEVICES THAT CONTAIN THEM
EA009376B1 (en) Nucleic acids specifically binding bioactive ghrelin
WO2006042001A3 (en) Stable three enzyme creatinine biosensor
KR20190016148A (en) Euglobulin-based method for determining the biological activity of defibrotide
WO2001097871A3 (en) Collagen hemostatic pellets
IL230453A (en) Composition comprising collagen for use in implantation of biological material
RU2170935C1 (en) Differential diagnosis method for determining destructive changes in the cases of acute cholecystitis
JP2014234384A (en) Alcohol metabolism accelerator
Inada et al. Immobilized L-asparaginase embedded in fibrin polymer
DE10394363D2 (en) New chelidonine derivatives, process for their preparation and their use for the preparation of pharmaceutical active ingredients
WO2004053093A2 (en) Method of inhibiting neural transmission mediated by serotonin-2a and enhancing sensorimotor gating
Javaid et al. Timed-release tablets employing lipase-lipid-sulfamethizole systems prepared by spray congealing
DE60117180D1 (en) METHOD FOR MEASURING THE ACTIVATION CONDITION OF SIGNALING PATHS IN CELLS
BR9813515A (en) Blueene hydroxamic acid derivatives as metalloprotein inhibitors
Amran et al. The in vitro effects of atenolol and zinc chloride on the protein binding of amlodipine in aqueous medium
Saldanha et al. Erythrocyte acetylcholinesterase is a signaling receptor
EP2244584A1 (en) Process for preparing feed and feed additives of enhanced nutritive value from industrial by-products containing vegetable oils
Buts et al. Changes in serum and intestinal diamine oxidase (DAO) activity after proximal enterectomy in rats: Correlation of DAO activity with mucosal mass parameters
CA2399219A1 (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
SU1433975A1 (en) Method of activating pressed bakery yeast

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060327